# ![@BicaraTx Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1261701084478914562.png) @BicaraTx Bicara Therapeutics

Bicara Therapeutics posts on X about bicara, alfa, study, science the most. They currently have [-----] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: undefined [#](/creator/twitter::1261701084478914562/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1261701084478914562/c:line/m:interactions.svg)

- [--] Week [--] +4.40%
- [--] Month [---] +321%
- [--] Months [-----] +5,612%
- [--] Year [-----] +57%

### Mentions: undefined [#](/creator/twitter::1261701084478914562/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1261701084478914562/c:line/m:posts_active.svg)

- [--] Week [--] no change
- [--] Month [--] +700%
- [--] Months [--] +71%
- [--] Year [--] +960%

### Followers: [-----] [#](/creator/twitter::1261701084478914562/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1261701084478914562/c:line/m:followers.svg)

- [--] Week [---] -0.40%
- [--] Month [---] -0.40%
- [--] Months [---] +8.30%
- [--] Year [---] +8.80%

### CreatorRank: undefined [#](/creator/twitter::1261701084478914562/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1261701084478914562/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [finance](/list/finance)  [financial services](/list/financial-services)  [exchanges](/list/exchanges) 

**Social topic influence**
[bicara](/topic/bicara), [alfa](/topic/alfa), [study](/topic/study), [science](/topic/science), [ceo](/topic/ceo), [we are](/topic/we-are), [head and](/topic/head-and), [more than](/topic/more-than), [share](/topic/share), [business](/topic/business)

**Top assets mentioned**
[Bicara Therapeutics Inc. (BCAX)](/topic/$bcax) [Goldman Sachs (GS)](/topic/goldman-sachs)
### Top Social Posts
Top posts by engagements in the last [--] hours

"We're excited to share that we've closed our IPO & are listed on Nasdaq as $BCAX This marks an important new chapter for our company as we aim to deliver transformative bifunctional therapies to patients with solid tumors. Thanks to all of our dedicated team members & partners"  
[X Link](https://x.com/BicaraTx/status/1835772262630474209)  2024-09-16T20:06Z [---] followers, [----] engagements


"This morning we announced our third quarter [----] financial results and business update highlighting the strong development progress we have made with ficerafusp alfa and the successful completion of our upsized initial public offering. For more details read the full press release here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2024-financial-results https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2024-financial-results"  
[X Link](https://x.com/BicaraTx/status/1856314632685617269)  2024-11-12T12:34Z [---] followers, [---] engagements


"Our lead program ficerafusp alfa offers the potential to better control tumor growth leading to more durable responses an improved therapeutic window & ultimately better outcomes for #cancer patients. Find out how were driving the development of ficerafusp alfa across #HNSCC & other solid tumors by visiting https://www.bicara.com/patients/ https://www.bicara.com/patients/"  
[X Link](https://x.com/BicaraTx/status/1901992916941234322)  2025-03-18T13:43Z [---] followers, [----] engagements


"Today we announce our first publication in @CR_AACR. This manuscript describes the design & characterization of BCA101 a #firstinclass dual-action bifunctional antibody designed to inhibit EGFR & disable TGF- directly at the tumor site. https://www.bicara.com/bicara-therapeutics-announces-publication-in-cancer-research-describing-design-and-characterization-of-lead-bifunctional-antibody-program-bca101/ https://www.bicara.com/bicara-therapeutics-announces-publication-in-cancer-research-describing-design-and-characterization-of-lead-bifunctional-antibody-program-bca101/"  
[X Link](https://x.com/BicaraTx/status/1648716017240088579)  2023-04-19T15:51Z [---] followers, [---] engagements


"We announced the first patients have been enrolled in FORTIFI-HN01 a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L R/M HNSCC. Read more here: #headandneckcancer https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-first-patients-enrolled-fortifi https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-first-patients-enrolled-fortifi"  
[X Link](https://x.com/BicaraTx/status/1889660735518892188)  2025-02-12T13:00Z [---] followers, [---] engagements


"Members of the Bicara management team will participate in the Stifel [----] Virtual Targeted Oncology Forum on Tuesday April [--] [----]. To access the live webcast and replay visit our website at https://ir.bicara.com/news-events/events-and-presentations https://ir.bicara.com/news-events/events-and-presentations"  
[X Link](https://x.com/BicaraTx/status/1907055048925880617)  2025-04-01T12:58Z [---] followers, [--] engagements


"April is #HeadAndNeckCancer Awareness Montha time to recognize the thousands of patients in the U.S. facing a diagnosis this year. These cancers make up about 4% of all #cancer cases nationwide. At Bicara we're committed to transforming care for patients with solid tumors. Through innovative first-in-class therapeutics we strive to not only enhance treatment but extend lives. With a relentless focus on progress collaboration and scientific innovation we're pushing boundaries to revolutionize cancer care. https://twitter.com/i/web/status/1907854100487667958"  
[X Link](https://x.com/BicaraTx/status/1907854100487667958)  2025-04-03T17:53Z [---] followers, [--] engagements


"Congratulations to our incredible research team on their latest publication Deciphering T-cell exhaustion in the tumor microenvironment now out in Frontiers in Immunology. This work deepens our understanding of T-cell exhaustion and its role in shaping immune responses in cancercritical insights for advancing novel immunotherapies. Read about it at https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1548234/full https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1548234/full"  
[X Link](https://x.com/BicaraTx/status/1908134898092610003)  2025-04-04T12:29Z [---] followers, [--] engagements


"Ficerafusp alfa is currently being evaluated in patients with 1L R/M HNSCC with the potential for broader clinical development in other #HNSCC populations. Ficerafusp alfa may also provide meaningful benefits in other EGFR-expressing squamous cell tumors due to its dual-inhibition of EGFR and TGF- pathways. View the full video at https://www.bicara.com/science/ https://www.bicara.com/science/"  
[X Link](https://x.com/BicaraTx/status/1910323222764990709)  2025-04-10T13:25Z [---] followers, [---] engagements


"At Bicara our commitment to people living with head and neck cancer goes far beyond science; were driven by one thing: people. This #HeadAndNeckCancer Awareness Month we made pins and came together to raise awareness for the patients who inspire us every day. The science matters but so does the heart behind it. https://twitter.com/i/web/status/1913230860947542028 https://twitter.com/i/web/status/1913230860947542028"  
[X Link](https://x.com/BicaraTx/status/1913230860947542028)  2025-04-18T13:59Z [---] followers, [--] engagements


"This year at #SITC25 we shared preclinical data showing that dual targeting of TGF- and EGFR with ficerafusp alfa led to superior antitumor activity in colorectal #cancer models. The results further support its potential as a novel approach for solid tumors. Were inspired by the innovation & collaboration at #SITC25 & remain driven to advance transformative science that improves patient outcomes"  
[X Link](https://x.com/BicaraTx/status/1988999789036417179)  2025-11-13T15:57Z [---] followers, [----] engagements


"Bicara Therapeutics to Present Clinical Data from Lead Precision Tumor Modulator Program BCA101 at @myESMO Congress [----] - https://www.businesswire.com/news/home/20220818005125/en/Bicara-Therapeutics-to-Present-Clinical-Data-from-Lead-Precision-Tumor-Modulator-Program-BCA101-at-ESMO-Congress-2022utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork"  
[X Link](https://x.com/BicaraTx/status/1562199048072749057)  2022-08-23T22:04Z [---] followers, [--] engagements


"Were looking forward to presenting preclinical data on BCA356 a precision immunocytokine at the Society for Immunotherapy of Cancer (SITC) Annual Meeting this week in Boston. @sitcancer For more info: https://www.bicara.com/bicara-therapeutics-presents-preclinical-data-for-precision-immunocytokine-bca356-at-society-for-immunotherapy-of-cancer-sitc-2022-annual-meeting/ https://www.bicara.com/bicara-therapeutics-presents-preclinical-data-for-precision-immunocytokine-bca356-at-society-for-immunotherapy-of-cancer-sitc-2022-annual-meeting/"  
[X Link](https://x.com/BicaraTx/status/1589730847275433984)  2022-11-07T21:25Z [---] followers, [--] engagements


"Were excited to announce that Bicara CEO Claire Mazumdar will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11th with an update on our work to develop dual-action biologics to treat cancer. #JPM23 #jpm2023 https://www.bicara.com/bicara-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference/ https://www.bicara.com/bicara-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference/"  
[X Link](https://x.com/BicaraTx/status/1610647810642219010)  2023-01-04T14:42Z [---] followers, [---] engagements


"We are so thrilled to announce a $108M Series B financing to advance our clinical-stage pipeline to treat cancer. Were grateful for the hard work of our team & the support of co-lead investors #RedTreeVentureCapital & #RACapital & our other of investors. https://bit.ly/series-b-funding https://bit.ly/series-b-funding"  
[X Link](https://x.com/BicaraTx/status/1632724326184112128)  2023-03-06T12:46Z [---] followers, [---] engagements


"We are excited to share data supporting the ongoing #clinicaldevelopment of our lead candidate #BCA101 at the #AACR23 later this month. Bicara's work to tackle #headandneckcancer will be featured in [--] poster sessions. #collaboration #bca101 https://www.bicara.com/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023/ https://www.bicara.com/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023/"  
[X Link](https://x.com/BicaraTx/status/1643245674664714241)  2023-04-04T13:34Z [---] followers, [---] engagements


"Announcing the upcoming oral presentation at #ASCO23 of dose expansion data in #headandneckcancer from the Phase 1/1b study of Bicara's lead candidate #BCA101. #CancerResearch #targetedtherapy #collaboration https://www.bicara.com/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting/ https://www.bicara.com/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting/"  
[X Link](https://x.com/BicaraTx/status/1651240321831821314)  2023-04-26T15:02Z [---] followers, [---] engagements


"We're headed to the #JefferiesHealthcare conference Join us June [--] and learn more about how we are combining the precision of targeted therapies and the power of tumor modulators. https://www.businesswire.com/news/home/20230601006052/en/Bicara-Therapeutics-to-Present-at-the-2023-Jefferies-Global-Healthcare-Conference https://www.businesswire.com/news/home/20230601006052/en/Bicara-Therapeutics-to-Present-at-the-2023-Jefferies-Global-Healthcare-Conference"  
[X Link](https://x.com/BicaraTx/status/1664373901202272257)  2023-06-01T20:50Z [---] followers, [---] engagements


"We're thrilled to welcome David Raben M.D. to Bicara as CMO Dr. Raben's more than [--] years of biopharma and academic translational #oncology comes at the right time as we continue to execute in the clinic and enter our next phase of growth. https://www.bicara.com/bicara-therapeutics-expands-management-team-with-the-appointment-of-david-raben-m-d-as-chief-medical-officer/ https://www.bicara.com/bicara-therapeutics-expands-management-team-with-the-appointment-of-david-raben-m-d-as-chief-medical-officer/"  
[X Link](https://x.com/BicaraTx/status/1683451547877797890)  2023-07-24T12:18Z [---] followers, [---] engagements


"We're thrilled to announce the completion of our oversubscribed $165M Series C financing building on our momentum as we workto provide first-in-class meaningful therapies to #cancer patients. Read more here: https://www.bicara.com/bicara-therapeutics-announces-oversubscribed-165-million-series-c-financing/ https://www.bicara.com/bicara-therapeutics-announces-oversubscribed-165-million-series-c-financing/"  
[X Link](https://x.com/BicaraTx/status/1734537242498965918)  2023-12-12T11:34Z [---] followers, [----] engagements


"Were attending the TD Cowen 45th Annual Health Care Conference in Boston MA. Bicara CEO Claire Mazumdar will be presenting on Mon Mar [--] to share insights on Bicaras recent progress. Visit here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-present-td-cowen-45th-annual-health-care https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-present-td-cowen-45th-annual-health-care"  
[X Link](https://x.com/BicaraTx/status/1894392241960968251)  2025-02-25T14:21Z [---] followers, [---] engagements


"We are pleased to share that three abstracts relating to our lead product candidate ficerafusp alfa will be presented at the upcoming @AACR Annual Meeting [----]. To learn more about the details of the poster presentations visit https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-upcoming-presentations-aacr-annual https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-upcoming-presentations-aacr-annual"  
[X Link](https://x.com/BicaraTx/status/1904640457914581064)  2025-03-25T21:04Z [---] followers, [----] engagements


"Today we announced our fourth quarter and full year [----] financial results and business update highlighting continued progress across our pipeline. For more details read the full press release here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-fourth-quarter-and-full-year-2024 https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-fourth-quarter-and-full-year-2024"  
[X Link](https://x.com/BicaraTx/status/1905222370496823734)  2025-03-27T11:36Z [---] followers, [--] engagements


"We are pleased to announce our oral presentation at the [----] @ASCO Annual Meeting. We will share updated data from our ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L R/M HNSCC. To learn more about the details of the presentation visit #ASCO25 https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-present-updated-data-ongoing-phase-11b-trial https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-present-updated-data-ongoing-phase-11b-trial"  
[X Link](https://x.com/BicaraTx/status/1915045888244039748)  2025-04-23T14:11Z [---] followers, [---] engagements


"Members of the Bicara team participated in multiple presentations relating to ficerafusp alfa at the @aacr Annual Meeting [----]. These presentations highlight the broad therapeutic potential of ficerafusp alfa for solid tumors. Learn more about all the data presented here: #AACR25 https://www.globenewswire.com/news-release/2025/04/28/3069630/0/en/Bicara-Therapeutics-Highlights-Broad-Potential-of-Ficerafusp-Alfa-at-AACR-Annual-Meeting-2025.html"  
[X Link](https://x.com/BicaraTx/status/1916947111268004160)  2025-04-28T20:06Z [---] followers, [---] engagements


"A head and neck #cancer diagnosis can be overwhelming but patients deserve more than treatmentthey deserve hope. We're developing next-generation biologics designed to precisely target tumors and reshape the tumor environment striving for better outcomes with less burden on patients. As we wrap up #HeadAndNeckCancer Awareness Month we honor the strength of those facing this disease and remain committed to advancing innovative therapies that put patients first. Progress begins with understanding advocacy and science that drives real change. https://twitter.com/i/web/status/1917572681622499771"  
[X Link](https://x.com/BicaraTx/status/1917572681622499771)  2025-04-30T13:32Z [---] followers, [---] engagements


"Today we announced our first quarter [----] financial results and business update highlighting continued execution across our clinical programs. For more details read the full press release here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-first-quarter-2025-financial-results https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-first-quarter-2025-financial-results"  
[X Link](https://x.com/BicaraTx/status/1922253978496037250)  2025-05-13T11:33Z [---] followers, [---] engagements


"Today we announced the publication of an abstract with updated interim data from our Phase 1/1b clinical trial of ficerafusp alfa in 1L R/M HNSCC on the ASCO website. We look forward to hosting a conference call on Sun June [--] during #ASCO25 to share the fulsome dataset. To learn more and register visit: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-publication-abstract-updated https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-publication-abstract-updated"  
[X Link](https://x.com/BicaraTx/status/1925659143894864061)  2025-05-22T21:04Z [---] followers, [---] engagements


"Details: Today were sharing updated data at #ASCO25 from the Phase 1/1b clinical trial of ficerafusp alfa in 1L HPV-negative R/M #HNSCC. These findings demonstrated deep & durable responses translating to a median duration of response of [----] months & provide compelling support for the continued advancement of our pivotal Phase 2/3 trial of FORTIFI-HN01. A conference call & webcast will be available today at 3:00 P.M. CT / 4:00 P.M. ET. https://twitter.com/i/web/status/1929225394189639924"  
[X Link](https://x.com/BicaraTx/status/1929225394189639924)  2025-06-01T17:15Z [---] followers, [----] engagements


"Members of the Bicara management team will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday June [--]. To access the live webcast and replay visit our website at https://lnkd.in/gfy8e4NR https://lnkd.in/gfy8e4NR"  
[X Link](https://x.com/BicaraTx/status/1929992722519114055)  2025-06-03T20:04Z [---] followers, [--] engagements


"We're thrilled to share that CEO Claire Muzamdar has been named a [----] New England winner of the@EYNews #EntrepreneurOfTheYear award This recognition is a testament to Claire's bold vision & unwavering commitment to transformingtreatment for patients which translates to a culture of innovation at Bicara. We're also proud to celebrate Bicara board member Kate Haviland for receiving this recognition. It's a privilege to work alongside leaders who are reimaging what's possible in medicine. Congrats both on this well-deserved honor View the full list of finalists"  
[X Link](https://x.com/BicaraTx/status/1933171993672667445)  2025-06-12T14:38Z [---] followers, [--] engagements


"This June we recognize the more than [--] million in the U.S. who live with a history of cancer. That number is projected to reach [--] million by [----]. #NationalCancerSurvivorsMonth honors the strength and resilience of those impacted & highlights the importance of continued progress in detection care & treatment. At Bicara were working to bring transformative therapies to those impacted by solid tumor cancers. https://twitter.com/i/web/status/1934966731623027110 https://twitter.com/i/web/status/1934966731623027110"  
[X Link](https://x.com/BicaraTx/status/1934966731623027110)  2025-06-17T13:29Z [---] followers, [--] engagements


"Head & neck cancers account for nearly 4% of all cancers and if caught early carry an 80% survival rate but unfortunately early diagnosis is still too uncommon. At Bicara we believe working towards a future where more patients become survivors starts with education & awareness. Follow the four steps below and incorporate monthly self-exams into your routine to get familiar with what is normal for you. https://twitter.com/i/web/status/1937512611731398978 https://twitter.com/i/web/status/1937512611731398978"  
[X Link](https://x.com/BicaraTx/status/1937512611731398978)  2025-06-24T14:06Z [---] followers, [--] engagements


"Strong science starts with strong people. Meet Pauline Dufresne our Chief People Officer who brings [--] years of HR experience with the past decade in life sciences to help scale Bicara with purpose and care. Bicaras culture of high integrity perseverance and respect resonated with my personal values. I am also appreciative of the opportunity to work alongside exceptional leaders and to be tasked with the challenge of quickly scaling a late stage biotech company. She shares more below. https://twitter.com/i/web/status/1942926971417067707 https://twitter.com/i/web/status/1942926971417067707"  
[X Link](https://x.com/BicaraTx/status/1942926971417067707)  2025-07-09T12:41Z [---] followers, [--] engagements


"#DYK [--] in [--] kids in MA face clothing insecurity and may lack school-ready essentials Thats why we teamed up with @LS_Cares & @c2cboston to help by organizing backpacks clothes & supplies so local kids can start the school year strong. A powerful reminder that even simple things like a jacket or backpack can break down barriers to learning & play. Thank you to Cradles to Crayons for the opportunity to support your incredible mission & to our amazing team for showing up with hearts & hands to give back together. https://twitter.com/i/web/status/1945855604993761467"  
[X Link](https://x.com/BicaraTx/status/1945855604993761467)  2025-07-17T14:38Z [---] followers, [--] engagements


"#HNSCC remains one of the leading causes of cancer-related death & disability across the globe & incidence rates are projected to increase by 30% by [----]. This past Sunday was #WorldHeadAndNeckCancerDay which serves as a reminder for our shared responsibility to support those affected and reinforces our commitment to advancing science that can truly change the lives of people living with HNSCC. https://twitter.com/i/web/status/1950234089174552980 https://twitter.com/i/web/status/1950234089174552980"  
[X Link](https://x.com/BicaraTx/status/1950234089174552980)  2025-07-29T16:36Z [---] followers, [----] engagements


"Today we announced our second quarter [----] financial results and business update. For more details read the full press release here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-second-quarter-2025-financial https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-second-quarter-2025-financial"  
[X Link](https://x.com/BicaraTx/status/1955231690420285670)  2025-08-12T11:35Z [---] followers, [--] engagements


"For more info visit: Ficerafusp alfa is being evaluated in FORTIFI-HN01 a pivotal Phase 2/3 trial with pembrolizumab in 1L R/M #HNSCC. This global randomized double-blinded placebo-controlled study will enroll [---] patients excluding HPV+ OPSCC to focus on a high-risk population with few options. FORTIFI-HN01 reflects our commitment to advancing precision immunotherapy where unmet need is the highest. https://www.bicara.com/patients/ https://www.bicara.com/patients/ https://www.bicara.com/patients/ https://www.bicara.com/patients/"  
[X Link](https://x.com/BicaraTx/status/1958170755046236458)  2025-08-20T14:14Z [---] followers, [---] engagements


"With a growing team & exciting progress happening at Bicara we came together in Boston for two days of connection & alignment - kicking things off with a Red Sox outing & continuing with our company-wide All Hands offsite. We heard from inspiring guest speakers strengthened cross-team connections and aligned on priorities that will drive us forward in our mission to bring new therapies to patients. Were grateful for this team and excited to carry this momentum forward https://twitter.com/i/web/status/1960338349366837521 https://twitter.com/i/web/status/1960338349366837521"  
[X Link](https://x.com/BicaraTx/status/1960338349366837521)  2025-08-26T13:47Z [---] followers, [---] engagements


"Bicara leadership will be attending several investor conferences in September. We look forward to sharing updates on the progress of our lead program ficerafusp alfa and our approach to addressing the significant unmet needs for patients with various solid tumors. To access the live webcasts and replays visit our website at https://ir.bicara.com/news-events/events-and-presentations https://ir.bicara.com/news-events/events-and-presentations"  
[X Link](https://x.com/BicaraTx/status/1961056518087856147)  2025-08-28T13:21Z [---] followers, [--] engagements


"Congratulations to our CEO Claire Mazumdar on being named a #Fierce50 honoree in the leadership category. This recognition highlights Claires visionary leadership at Bicara - driving meaningful change advancing first-in-class treatments and inspiring a culture of innovation that puts patients first. Full list here: https://www.fiercepharma.com/collection/fierce-50-2025 https://www.fiercepharma.com/collection/fierce-50-2025"  
[X Link](https://x.com/BicaraTx/status/1962882034818261061)  2025-09-02T14:15Z [---] followers, [----] engagements


"#DYK roughly 80% of R/M #HNSCC cases are HPV-negative a subtype with significantly worse prognosis compared to HPV-positive disease HPV-negative #HNSCC is especially difficult with tumors that often recur locally and life-altering risks including fatal bleeding severe pain and difficulty swallowing. At Bicara were committed to advancing better therapeutic options for HPV-negative patients through our pivotal FORTIFI-HN01 trial evaluating ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC. Learn more at https://www.bicara.com/patients/"  
[X Link](https://x.com/BicaraTx/status/1966504162499150066)  2025-09-12T14:08Z [---] followers, [--] engagements


"It's officially been one year since $BCAX became a publicly traded company Over the last year thanks to the dedication of our team weve made tremendous progress toward our mission to improve the lives of people living with #cancer through the development of innovative targeted therapies. Heres to building on that momentum & to another year of progress for patients. https://twitter.com/i/web/status/1967933739121643773 https://twitter.com/i/web/status/1967933739121643773"  
[X Link](https://x.com/BicaraTx/status/1967933739121643773)  2025-09-16T12:49Z [---] followers, [---] engagements


"Our team is the heart of Bicara. Were united by a shared commitment to deliver meaningful therapies for people living with #cancer while creating an environment where everyone can grow learn & thrive. By bringing together diverse backgrounds and perspectives we amplify the impact we can have for patients. https://twitter.com/i/web/status/1968699462122864721 https://twitter.com/i/web/status/1968699462122864721"  
[X Link](https://x.com/BicaraTx/status/1968699462122864721)  2025-09-18T15:31Z [---] followers, [--] engagements


"Today is #WorldCancerResearchDay a reminder of the vital role research plays in transforming #cancer care. At Bicara we are driven by urgency & dedication to bring forward innovative therapies that put our patients first. Liz shares how she began her career in #oncology & the importance of clinical research. https://twitter.com/i/web/status/1970839254625329163 https://twitter.com/i/web/status/1970839254625329163"  
[X Link](https://x.com/BicaraTx/status/1970839254625329163)  2025-09-24T13:14Z [---] followers, [--] engagements


"Were pleased to share that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) for ficerafusp alfa in combination with pembrolizumab for the treatment of patients with 1L HPV-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (#HNSCC). This designation underscores the significant unmet need in HPV-negative R/M HNSCC and reinforces our commitment to advancing ficerafusp alfa to patients as quickly as possible. Learn more here:"  
[X Link](https://x.com/BicaraTx/status/1977699465575211158)  2025-10-13T11:34Z [---] followers, [---] engagements


"Were thrilled to introduce three new members of our leadership team who bring with them a deep expertise and passion for advancing #oncology innovation. We look forward to the leadership and insight they bring as we advance our mission to transform the lives of people living with cancer. https://twitter.com/i/web/status/1978143844408438986 https://twitter.com/i/web/status/1978143844408438986"  
[X Link](https://x.com/BicaraTx/status/1978143844408438986)  2025-10-14T17:00Z [---] followers, [--] engagements


"Members of Bicarawere proud to attend #ESMO25 where we connected with colleagues collaborators and innovators across the #oncology community. Each year this meeting reinforces the momentum and shared commitment driving new possibilities for people living with #cancer"  
[X Link](https://x.com/BicaraTx/status/1981451593469088036)  2025-10-23T20:04Z [---] followers, [--] engagements


"Proud to see our CEO Claire Mazumdar recognized among the @BosBizJournals [----] Women Who Lead in Life Sciences honoring leaders shaping innovation & impact across biotech. Thanks to BBJ for hosting an inspiring event honoring women who are leading the way in life sciences"  
[X Link](https://x.com/anyuser/status/1983544826248458396)  2025-10-29T14:41Z [---] followers, [----] engagements


"Not all head and neck cancers are the same. Head and neck squamous cell carcinoma (#HNSCC) is a diverse disease with important biological differences between HPV-positive and HPV-negative tumors. These differences influence how patients respond to therapy and underscore the need for more precise targeted treatment approaches. This ESMO Daily Reporter opinion piece highlights why researchers must learn from the biology of HNSCC and adapt clinical trial designs to focus on more homogeneous patient populations including those with HPV-negative disease. At Bicara we're guided by this evolving"  
[X Link](https://x.com/anyuser/status/1983977826144469080)  2025-10-30T19:22Z [---] followers, [----] engagements


"This morning we announced our third quarter [----] financial results and business update highlighting our recent breakthrough therapy designation for ficerafusp alfa in 1L HPV-negative #HNSCC & upcoming conference participation. For more details read the full press release here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2025-financial-results https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2025-financial-results"  
[X Link](https://x.com/anyuser/status/1987865971864863227)  2025-11-10T12:52Z [---] followers, [--] engagements


"This year at #SITC25 we shared preclinical data showing that dual targeting of TGF- and EGFR with ficerafusp alfa led to superior antitumor activity in colorectal #cancer models. The results further support its potential as a novel approach for solid tumors. Were inspired by the innovation & collaboration at #SITC25 & remain driven to advance transformative science that improves patient outcomes. View the poster here: https://www.bicara.com/wp-content/uploads/2025/11/SITC-2025_ePoster_1180.pdf https://www.bicara.com/wp-content/uploads/2025/11/SITC-2025_ePoster_1180.pdf"  
[X Link](https://x.com/anyuser/status/1989005410955616594)  2025-11-13T16:20Z [---] followers, [--] engagements


"Were excited to share that Bicara has been nominated for the Next Cornerstone Healthcare Company of the Year at the 13th Annual #NEVYs25 Thank you to the @NewEnglandVC for this meaningful recognition. At Bicara we are committed to developing first-in-class cancer therapeutics to both improve and extend the lives of patients who are impacted by solid tumor cancers. See the full list of nominees here: https://thenevys.com/2025-nominees/ https://thenevys.com/2025-nominees/"  
[X Link](https://x.com/anyuser/status/1991878143930413105)  2025-11-21T14:35Z [---] followers, [----] engagements


"Today we announced the publication of an abstract with early Phase 1b expansion cohort evaluating [---] mg of ficerafusp alfa weekly (QW) in combination with pembrolizumab in 1L HPV-negative R/M #HNSCC. These early data offer important insight into ficerafusp alfas safety and efficacy as we work towards dose selection for our ongoing pivotal FORTIFI-HN01 study. We look forward to hosting a conference call on Sat Dec [--] during #ESMOAsia25 to share more on the dataset. To learn more and register visit:"  
[X Link](https://x.com/anyuser/status/1995464460966793705)  2025-12-01T12:06Z [---] followers, [--] engagements


"We will host a conference call & webcast today at 9:00 a.m. ET. Details: Were excited to share early data from the Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly (QW) in combination with pembrolizumab in 1L HPV-negative R/M HNSCC today at #ESMOAsia25. Ficerafusp alfa the first and only bifunctional EGFR-directed antibody x TGF- ligand trap is purposefully designed to deliver deep durable responses with the potential to meaningfully extend overall survival for patients with HPV-negative disease. The data presented represent an important step in our dose-optimization"  
[X Link](https://x.com/anyuser/status/1997301736365584663)  2025-12-06T13:46Z [---] followers, [--] engagements


"We're looking forward to #JPM26 where CEO Claire Mazumdar will share insights on Bicaras progress of the ongoing pivotal FORTIFI-HN01 study and the potential of ficerafusp alfa for the treatment of multiple solid tumor cancers. View the details here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-present-jp-morgan-2026-annual-healthcare https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-present-jp-morgan-2026-annual-healthcare"  
[X Link](https://x.com/anyuser/status/2000552860237607108)  2025-12-15T13:05Z [---] followers, [---] engagements


"The holiday season reminds us of the importance of connection both with one another and our community. Were grateful to spend these moments together while giving back to Childrens Services of Roxbury @CSRoxbury in partnership with @LS_Cares"  
[X Link](https://x.com/anyuser/status/2003090132191310068)  2025-12-22T13:07Z [---] followers, [--] engagements


"Bicara is entering [----] with strong momentum. Today we shared our [----] outlook highlighted by selection of [----] mg of ficerafusp alfa as the optimal dose for Phase [--] of the FORTIFI-HN01 pivotal study a key milestone that sets the stage for continued execution this year. Read more here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides"  
[X Link](https://x.com/anyuser/status/2010701452029702311)  2026-01-12T13:12Z [---] followers, [--] engagements


"One week out and continuing to reflect on #JPM26. An energizing start to [----] and a meaningful moment for Bicara and our patients highlighted by the selection of [----] mg of ficerafusp alfa as the optimal dose in our Phase [--] FORTIFI-HN01 pivotal study. Grateful for our colleagues tuning in from Boston to support Claire on the podium. Moments like this are made possible by an incredible team. https://twitter.com/i/web/status/2013969384054669783 https://twitter.com/i/web/status/2013969384054669783"  
[X Link](https://x.com/anyuser/status/2013969384054669783)  2026-01-21T13:38Z [---] followers, [--] engagements


"Each year nearly [------] people globally are diagnosed with HPV-negative head and neck squamous cell carcinoma (#HNSCC) a statistic that represents far more than numbers but individuals families and communities forever changed. On #WorldCancerDay we honor the patients and the caregivers who stand alongside them. We remain steadfast in our commitment to advance meaningful new therapies for people living with cancer. https://twitter.com/i/web/status/2019134806366515298 https://twitter.com/i/web/status/2019134806366515298"  
[X Link](https://x.com/anyuser/status/2019134806366515298)  2026-02-04T19:43Z [---] followers, [--] engagements


"#February11 is the International Day of Women and Girls in Science a day to recognize the women of Bicara and their meaningful contributions to science. Each woman brings a perspective shaped by her own path into the field informing not only her work but how she shows up every day. Scroll through to hear from a few of our #WomenInScience and learn what sparked their curiosity and led them here. https://twitter.com/i/web/status/2021598172544487670 https://twitter.com/i/web/status/2021598172544487670"  
[X Link](https://x.com/anyuser/status/2021598172544487670)  2026-02-11T14:52Z [---] followers, [--] engagements


"An exciting moment for ourteam as we celebrated becoming a public company by ringing the #OpeningBell at @Nasdaq This marks a new chapter in developing therapies for those living w/ #cancer. Thanks to our hard working & talented team who made this achievement possible. $BCAX"  
[X Link](https://x.com/anyuser/status/1838986361006924263)  2024-09-25T16:58Z [---] followers, [----] engagements


"#February11 is the International Day of Women and Girls in Science a day to recognize the women of Bicara and their meaningful contributions to science. Each woman brings a perspective shaped by her own path into the field informing not only her work but how she shows up every day. Scroll through to hear from a few of our #WomenInScience and learn what sparked their curiosity and led them here. https://twitter.com/i/web/status/2021598172544487670 https://twitter.com/i/web/status/2021598172544487670"  
[X Link](https://x.com/anyuser/status/2021598172544487670)  2026-02-11T14:52Z [---] followers, [--] engagements


"Each year nearly [------] people globally are diagnosed with HPV-negative head and neck squamous cell carcinoma (#HNSCC) a statistic that represents far more than numbers but individuals families and communities forever changed. On #WorldCancerDay we honor the patients and the caregivers who stand alongside them. We remain steadfast in our commitment to advance meaningful new therapies for people living with cancer. https://twitter.com/i/web/status/2019134806366515298 https://twitter.com/i/web/status/2019134806366515298"  
[X Link](https://x.com/anyuser/status/2019134806366515298)  2026-02-04T19:43Z [---] followers, [--] engagements


"At Bicara culture isnt a buzzword - its foundational. Its built on integrity fueled by curiosity and ambition and anchored by a shared commitment to delivering meaningful therapies to patients. Advancing science isnt just about what we do but how we do it. We celebrate progress learn from challenges and move forward together with purpose - always keeping patients at the center of everything we do"  
[X Link](https://x.com/anyuser/status/2016884245340303789)  2026-01-29T14:40Z [---] followers, [--] engagements


"One week out and continuing to reflect on #JPM26. An energizing start to [----] and a meaningful moment for Bicara and our patients highlighted by the selection of [----] mg of ficerafusp alfa as the optimal dose in our Phase [--] FORTIFI-HN01 pivotal study. Grateful for our colleagues tuning in from Boston to support Claire on the podium. Moments like this are made possible by an incredible team. https://twitter.com/i/web/status/2013969384054669783 https://twitter.com/i/web/status/2013969384054669783"  
[X Link](https://x.com/anyuser/status/2013969384054669783)  2026-01-21T13:38Z [---] followers, [--] engagements


"Bicara is entering [----] with strong momentum. Today we shared our [----] outlook highlighted by selection of [----] mg of ficerafusp alfa as the optimal dose for Phase [--] of the FORTIFI-HN01 pivotal study a key milestone that sets the stage for continued execution this year. Read more here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides"  
[X Link](https://x.com/anyuser/status/2010701452029702311)  2026-01-12T13:12Z [---] followers, [--] engagements


"The holiday season reminds us of the importance of connection both with one another and our community. Were grateful to spend these moments together while giving back to Childrens Services of Roxbury @CSRoxbury in partnership with @LS_Cares"  
[X Link](https://x.com/anyuser/status/2003090132191310068)  2025-12-22T13:07Z [---] followers, [--] engagements


"Are you or a loved one living with head and neck cancer The FORTIFI-HN01 trial is a pivotal Phase 2/3 study evaluating a potential new treatment option and is currently enrolling patients. @BicaraTx #ClinicalTrial #HeadAndNeckCancer #CancerResearch https://clinicaltrials.gov/study/NCT06788990 https://clinicaltrials.gov/study/NCT06788990"  
[X Link](https://x.com/anyuser/status/1996966797757604244)  2025-12-05T15:36Z [----] followers, [---] engagements


"We're looking forward to #JPM26 where CEO Claire Mazumdar will share insights on Bicaras progress of the ongoing pivotal FORTIFI-HN01 study and the potential of ficerafusp alfa for the treatment of multiple solid tumor cancers. View the details here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-present-jp-morgan-2026-annual-healthcare https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-present-jp-morgan-2026-annual-healthcare"  
[X Link](https://x.com/anyuser/status/2000552860237607108)  2025-12-15T13:05Z [---] followers, [---] engagements


"We will host a conference call & webcast today at 9:00 a.m. ET. Details: Were excited to share early data from the Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly (QW) in combination with pembrolizumab in 1L HPV-negative R/M HNSCC today at #ESMOAsia25. Ficerafusp alfa the first and only bifunctional EGFR-directed antibody x TGF- ligand trap is purposefully designed to deliver deep durable responses with the potential to meaningfully extend overall survival for patients with HPV-negative disease. The data presented represent an important step in our dose-optimization"  
[X Link](https://x.com/anyuser/status/1997301736365584663)  2025-12-06T13:46Z [---] followers, [--] engagements


"Today we announced the publication of an abstract with early Phase 1b expansion cohort evaluating [---] mg of ficerafusp alfa weekly (QW) in combination with pembrolizumab in 1L HPV-negative R/M #HNSCC. These early data offer important insight into ficerafusp alfas safety and efficacy as we work towards dose selection for our ongoing pivotal FORTIFI-HN01 study. We look forward to hosting a conference call on Sat Dec [--] during #ESMOAsia25 to share more on the dataset. To learn more and register visit:"  
[X Link](https://x.com/anyuser/status/1995464460966793705)  2025-12-01T12:06Z [---] followers, [--] engagements


"Were excited to share that Bicara has been nominated for the Next Cornerstone Healthcare Company of the Year at the 13th Annual #NEVYs25 Thank you to the @NewEnglandVC for this meaningful recognition. At Bicara we are committed to developing first-in-class cancer therapeutics to both improve and extend the lives of patients who are impacted by solid tumor cancers. See the full list of nominees here: https://thenevys.com/2025-nominees/ https://thenevys.com/2025-nominees/"  
[X Link](https://x.com/anyuser/status/1991878143930413105)  2025-11-21T14:35Z [---] followers, [----] engagements


"Are you or a loved one living with head and neck cancer The FORTIFI-HN01 trial is a pivotal Phase 2/3 study evaluating a potential new treatment option and is currently enrolling patients. @BicaraTx #ClinicalTrial #HeadAndNeckCancer #CancerResearch https://clinicaltrials.gov/study/NCT06788990 https://clinicaltrials.gov/study/NCT06788990"  
[X Link](https://x.com/anyuser/status/1990442572372754940)  2025-11-17T15:31Z [----] followers, [---] engagements


"This year at #SITC25 we shared preclinical data showing that dual targeting of TGF- and EGFR with ficerafusp alfa led to superior antitumor activity in colorectal #cancer models. The results further support its potential as a novel approach for solid tumors. Were inspired by the innovation & collaboration at #SITC25 & remain driven to advance transformative science that improves patient outcomes. View the poster here: https://www.bicara.com/wp-content/uploads/2025/11/SITC-2025_ePoster_1180.pdf https://www.bicara.com/wp-content/uploads/2025/11/SITC-2025_ePoster_1180.pdf"  
[X Link](https://x.com/anyuser/status/1989005410955616594)  2025-11-13T16:20Z [---] followers, [--] engagements


"More than 60K Americans annually are diagnosed with #HNSCC a disease disproportionately impacting U.S. veterans 2-3x higher than the general population. This #VeteransDay we extend our deepest gratitude to those who have served & to those now facing the toughest battle of all #cancer. At Bicara we believe that true innovation pairs with inclusivity fueling our commitment to advancing science expanding access & serving with compassion & respect every day to support our troops"  
[X Link](https://x.com/anyuser/status/1988259611397234746)  2025-11-11T14:56Z [---] followers, [--] engagements


"This morning we announced our third quarter [----] financial results and business update highlighting our recent breakthrough therapy designation for ficerafusp alfa in 1L HPV-negative #HNSCC & upcoming conference participation. For more details read the full press release here: https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2025-financial-results https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2025-financial-results"  
[X Link](https://x.com/anyuser/status/1987865971864863227)  2025-11-10T12:52Z [---] followers, [--] engagements


"Not all head and neck cancers are the same. Head and neck squamous cell carcinoma (#HNSCC) is a diverse disease with important biological differences between HPV-positive and HPV-negative tumors. These differences influence how patients respond to therapy and underscore the need for more precise targeted treatment approaches. This ESMO Daily Reporter opinion piece highlights why researchers must learn from the biology of HNSCC and adapt clinical trial designs to focus on more homogeneous patient populations including those with HPV-negative disease. At Bicara we're guided by this evolving"  
[X Link](https://x.com/anyuser/status/1983977826144469080)  2025-10-30T19:22Z [---] followers, [----] engagements


"Are you or a loved one living with head and neck cancer The FORTIFI-HN01 trial is a pivotal Phase 2/3 study evaluating a potential new treatment option and is currently enrolling patients. @BicaraTx #ClinicalTrial #HeadAndNeckCancer #CancerResearch https://clinicaltrials.gov/study/NCT06788990 https://clinicaltrials.gov/study/NCT06788990"  
[X Link](https://x.com/anyuser/status/1981017933087146255)  2025-10-22T15:20Z [----] followers, [---] engagements


"Proud to see our CEO Claire Mazumdar recognized among the @BosBizJournals [----] Women Who Lead in Life Sciences honoring leaders shaping innovation & impact across biotech. Thanks to BBJ for hosting an inspiring event honoring women who are leading the way in life sciences"  
[X Link](https://x.com/anyuser/status/1983544826248458396)  2025-10-29T14:41Z [---] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing